NOVEL FOOD · DOSSIER ANALYSIS · 20 SEPTEMBER 2026
Synthetic CBD in the EU: what EFSA’s positive 2026 opinion actually means
EFSA reached a positive safety conclusion for one precisely defined synthetic CBD application. That conclusion is material- and use-specific. It is not, by itself, permission to place CBD supplements on the EU market.
Positive EFSA opinion ≠ EU authorisation.
EFSA performs the scientific risk assessment. The European Commission then manages the authorisation process. A novel food may be lawfully marketed only after an applicable Commission act updates the Union list. No such authorisation is represented for this dossier here.
The opinion covers a specific CBD material and conditions of use.
The production process, composition, small-particle evidence, proposed use and target population are part of the assessment. Matching only the ingredient name “CBD” discards information that affected the scientific conclusion.
The dossier still has a risk-management gate.
EFSA also reported that proprietary information was necessary to reach its conclusion. This does not mean data protection has already been granted: any protection and permitted-user conditions must be read from the eventual authorising act.
A different synthetic CBD application reached a different result.
In a separate 2025 opinion, EFSA could not establish the safety of another proposed synthetic CBD material and use. Its stated purity, form, proposed daily intake and evidence package differed. The contrast is why a compliance system needs a material/dossier record, not a single ingredient-level “CBD status”.
≥98%, MCT oil, up to 2 mg/day, adults over 25 with defined exclusions.
Proposed ≥99.5% crystalline CBD and 30 mg/day; EFSA identified insufficient information.
Match the supplier material before interpreting the status.
Production method → purity → carrier → nanoparticle evidence → dose → population → supplier specification → Commission authorisation.
Read the opinion and the authorisation boundary.
EFSA Journal e10154 · 18 September 2026Positive opinion for the Chanelle McCoy CBD Ltd. dossier ↗European Commission · Novel Food authorisationsRisk assessment and Commission decision process ↗EFSA Journal e9527 · separate 2025 dossierSafety could not be established from the submitted evidence ↗Educational, source-backed analysis—not legal advice or a marketability decision. Always verify the current Union list, exact authorising act, product use and supplier material.